Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apnimed, Inc. announced the issuance of equity-based inducement grants to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
Stocks · News reference
Apnimed Q2 EPS $3.91 Beats $(0.34) Estimate, Sales $12.080M
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight
The obstructive sleep apnea (OSA) therapeutic landscape is rapidly expanding with 18+ companies developing 22+ pipeline drugs across multiple mechanisms of action. Eli Lilly's ZEPBOUND (tirzepatide) became the first FDA-approved pharmacological treatment for OSA in December 2024. Other major players including Apnimed, Amgen, Mosanna Therapeutics, and Incannex Healthcare are advancing late-stage candidates targeting weight loss, neuromuscular function, and airway control through diverse delivery methods.
8-K filing — Apnimed, Inc. (APMD)
Filed: 2026-09-08 AccNo: 0001193125-26-385355 Size: 619 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50
LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.
Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60
Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Apnimed (NASDAQ:APMD) with a Overweight rating and announces Price Target of $60.